Efficacy of Retreatments With Intravitreal Bevacizumab

Sponsor
Asociación para Evitar la Ceguera en México
Study ID
NCT00406744
Phase
PHASE3
Status
Terminated

Conditions

  • Age Related Macular Degeneration
  • Choroidal Neovascularization

Eligibility Criteria

Sex
ALL
Age
60 Years - 95 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

Key Dates

First listed
Dec 4, 2006
Start date
May 31, 2006
Status verified
May 2024
Primary completion
May 31, 2006
Completion
Nov 30, 2006

Study Design

Enrollment
20 participants (actual)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram

Related Studies